Pindolol augmentation of treatment-resistant depressed patients

Francisco Moreno, Alan J. Gelenberǵ, Karen Bachar, Pedro L. Delǵado

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Background: Recent uncontrolled reports describe a dramatic and rapid improvement of depressive symptoms in patients treated with the combination of pindolol and serotonin selective reuptake inhibitors or monoamine oxidase inhibitors. The present study attempts to replicate those findings. Method: Ten outpatients with current DSM-III-R major depressive disorder who had failed to obtain or maintain an appropriate response to an adequate trial of antidepressant drug were included in a randomized double-blind, placebo- controlled, crossover study. Subjects received pindolol 2.5 mg p.o. t.i.d. or placebo for 2 weeks in addition to their current antidepressant. Clinical monitoring, vital signs, and behavioral ratings were performed weekly for the duration of the study. Results: Pindolol was well tolerated by all patients. None of the subjects experienced significant symptom worsening during the addition of either placebo or active drug. At the end of the 2-week trial, there was no statistically significant difference between pindolol augmentation and placebo. Two patients had a categorical response during placebo treatment. No categorical responses were observed during pindolol augmentation. Conclusion: This study failed to replicate the rapid and dramatic response to pindolol augmentation in treatment-resistant depressed patients.

Original languageEnglish (US)
Pages (from-to)437-439
Number of pages3
JournalJournal of Clinical Psychiatry
Volume58
Issue number10
StatePublished - 1997

Fingerprint

Pindolol
Placebos
Antidepressive Agents
Therapeutics
Monoamine Oxidase Inhibitors
Vital Signs
Major Depressive Disorder
Serotonin Uptake Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Cross-Over Studies
Outpatients
Depression
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Moreno, F., Gelenberǵ, A. J., Bachar, K., & Delǵado, P. L. (1997). Pindolol augmentation of treatment-resistant depressed patients. Journal of Clinical Psychiatry, 58(10), 437-439.

Pindolol augmentation of treatment-resistant depressed patients. / Moreno, Francisco; Gelenberǵ, Alan J.; Bachar, Karen; Delǵado, Pedro L.

In: Journal of Clinical Psychiatry, Vol. 58, No. 10, 1997, p. 437-439.

Research output: Contribution to journalArticle

Moreno, F, Gelenberǵ, AJ, Bachar, K & Delǵado, PL 1997, 'Pindolol augmentation of treatment-resistant depressed patients', Journal of Clinical Psychiatry, vol. 58, no. 10, pp. 437-439.
Moreno, Francisco ; Gelenberǵ, Alan J. ; Bachar, Karen ; Delǵado, Pedro L. / Pindolol augmentation of treatment-resistant depressed patients. In: Journal of Clinical Psychiatry. 1997 ; Vol. 58, No. 10. pp. 437-439.
@article{e610abba34de4bac842bba131fdfe40d,
title = "Pindolol augmentation of treatment-resistant depressed patients",
abstract = "Background: Recent uncontrolled reports describe a dramatic and rapid improvement of depressive symptoms in patients treated with the combination of pindolol and serotonin selective reuptake inhibitors or monoamine oxidase inhibitors. The present study attempts to replicate those findings. Method: Ten outpatients with current DSM-III-R major depressive disorder who had failed to obtain or maintain an appropriate response to an adequate trial of antidepressant drug were included in a randomized double-blind, placebo- controlled, crossover study. Subjects received pindolol 2.5 mg p.o. t.i.d. or placebo for 2 weeks in addition to their current antidepressant. Clinical monitoring, vital signs, and behavioral ratings were performed weekly for the duration of the study. Results: Pindolol was well tolerated by all patients. None of the subjects experienced significant symptom worsening during the addition of either placebo or active drug. At the end of the 2-week trial, there was no statistically significant difference between pindolol augmentation and placebo. Two patients had a categorical response during placebo treatment. No categorical responses were observed during pindolol augmentation. Conclusion: This study failed to replicate the rapid and dramatic response to pindolol augmentation in treatment-resistant depressed patients.",
author = "Francisco Moreno and Gelenberǵ, {Alan J.} and Karen Bachar and Delǵado, {Pedro L.}",
year = "1997",
language = "English (US)",
volume = "58",
pages = "437--439",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "10",

}

TY - JOUR

T1 - Pindolol augmentation of treatment-resistant depressed patients

AU - Moreno, Francisco

AU - Gelenberǵ, Alan J.

AU - Bachar, Karen

AU - Delǵado, Pedro L.

PY - 1997

Y1 - 1997

N2 - Background: Recent uncontrolled reports describe a dramatic and rapid improvement of depressive symptoms in patients treated with the combination of pindolol and serotonin selective reuptake inhibitors or monoamine oxidase inhibitors. The present study attempts to replicate those findings. Method: Ten outpatients with current DSM-III-R major depressive disorder who had failed to obtain or maintain an appropriate response to an adequate trial of antidepressant drug were included in a randomized double-blind, placebo- controlled, crossover study. Subjects received pindolol 2.5 mg p.o. t.i.d. or placebo for 2 weeks in addition to their current antidepressant. Clinical monitoring, vital signs, and behavioral ratings were performed weekly for the duration of the study. Results: Pindolol was well tolerated by all patients. None of the subjects experienced significant symptom worsening during the addition of either placebo or active drug. At the end of the 2-week trial, there was no statistically significant difference between pindolol augmentation and placebo. Two patients had a categorical response during placebo treatment. No categorical responses were observed during pindolol augmentation. Conclusion: This study failed to replicate the rapid and dramatic response to pindolol augmentation in treatment-resistant depressed patients.

AB - Background: Recent uncontrolled reports describe a dramatic and rapid improvement of depressive symptoms in patients treated with the combination of pindolol and serotonin selective reuptake inhibitors or monoamine oxidase inhibitors. The present study attempts to replicate those findings. Method: Ten outpatients with current DSM-III-R major depressive disorder who had failed to obtain or maintain an appropriate response to an adequate trial of antidepressant drug were included in a randomized double-blind, placebo- controlled, crossover study. Subjects received pindolol 2.5 mg p.o. t.i.d. or placebo for 2 weeks in addition to their current antidepressant. Clinical monitoring, vital signs, and behavioral ratings were performed weekly for the duration of the study. Results: Pindolol was well tolerated by all patients. None of the subjects experienced significant symptom worsening during the addition of either placebo or active drug. At the end of the 2-week trial, there was no statistically significant difference between pindolol augmentation and placebo. Two patients had a categorical response during placebo treatment. No categorical responses were observed during pindolol augmentation. Conclusion: This study failed to replicate the rapid and dramatic response to pindolol augmentation in treatment-resistant depressed patients.

UR - http://www.scopus.com/inward/record.url?scp=0030697201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030697201&partnerID=8YFLogxK

M3 - Article

C2 - 9375594

AN - SCOPUS:0030697201

VL - 58

SP - 437

EP - 439

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 10

ER -